32 Biosciences, also known as "Three Squared Biosciences," is dedicated to transforming gut microbiome science into life-changing diagnostic and therapeutic solutions. The company originated from pioneering research at The University of Chicago and the University of Wisconsin-Madison. It was founded by Dr. John Alverdy, Dr. Eugene Chang, and Dr. Joseph Pierre, whose research uncovered the critical role of the gut microbial organ in human health. 32 Biosciences aims to develop innovative, microbiome-based diagnostics and interventions to address unmet medical needs and improve healthcare outcomes.

The company's vision is to establish the gut microbiome as the sixth vital organ globally recognized as a cornerstone of human health. They strive to lead the microbiome sector with advanced diagnostic tools and microbiome-based interventions. Their mission is to revolutionize healthcare by defining, diagnosing, and restoring the functional health of the gut microbiome to prevent and treat chronic diseases, ultimately improving health span and longevity.

32 Biosciences is a privately held biotechnology research company founded in 2023. The company is headquartered at 3333 Green Bay Rd, Suite 210 Innovation and Research Park, North Chicago, IL 60064, USA. The leadership includes Peter Farmakis (Chairman & CEO), Patrick Hennessey (Chief Medical Officer), Greg Aronin (Chief Operating Officer), and other key executives and advisory board members. They recently secured $6 million in funding to advance their gut microbiome platform technologies and are preparing for Series A and regulatory milestones.